FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial. PMID 39999660 · Atherosclerosis · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Postoperative changes in body composition after laparoscopic and open resection of colorectal liver metastases: data from the randomized OSLO-COMET trial. PMID 39994051 · Surg Endosc · 2025-Apr 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Effects of naloxegol on transit recovery in patients undergoing cardiac surgery: A randomized, double-blind, placebo-controlled trial. PMID 39988233 · Anaesth Crit Care Pain Med · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Extended Continuous Positive Airway Pressure in Preterm Infants Increases Lung Growth at 6 Months: A Randomized Controlled Trial. PMID 39977011 · Am J Respir Crit Care Med · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of Breast Density Educational Interventions on Mammography Screening Adherence Among Underserved Latinas: A Randomized Controlled Trial. PMID 39969957 · J Womens Health (Larchmt) · 2025-Apr The study is a randomized controlled trial with a primary time-to-event efficacy endpoint (Kaplan-Meier, HR) and is an original result. However, it is excluded because it does not involve a drug-containing intervention; the interventions are educational/informational (brochures, letters). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials. PMID 39969783 · Adv Ther · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Eligibility for donanemab trial in a population-based study of cognitive aging. PMID 39966022 · J Prev Alzheimers Dis · 2025-Apr The record describes a population-based study assessing eligibility criteria for a Phase III donanemab trial in Alzheimer's disease. It is not an oncology trial, does not report randomized trial results, and lacks a primary time-to-event efficacy endpoint (e.g., OS, PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial. PMID 39961315 · Lancet Diabetes Endocrinol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| MDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward. PMID 39955464 · CNS Drugs · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma. PMID 39955187 · Int J Gynecol Cancer · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A phase 2, placebo-controlled study to evaluate the efficacy and safety of BNC210, an alpha-7 nicotinic receptor negative allosteric modulator, for acute, as-needed treatment of social anxiety disorder (SAD) - The PREVAIL study. PMID 39954310 · Psychiatry Res · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis. PMID 39951042 · Diabetes Ther · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India. PMID 39950245 · Diabetes Obes Metab · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Preoperative visceral fat area predicts intraoperative adverse events during lymphadenectomy in laparoscopic gastrectomy for gastric cancer: a post hoc analysis. PMID 39937241 · Surg Endosc · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma. PMID 39932221 · Future Oncol · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
S
B
|
严格 v3 独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant-level analysis of the ONWARDS 1-5 trials. PMID 39930546 · Diabetes Obes Metab · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studies. PMID 39929260 · Contemp Clin Trials · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study. PMID 39923271 · Eur Neuropsychopharmacol · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial. PMID 39920394 · Nat Med · 2025-Apr The trial is a cluster-randomized trial in oncology with a primary OS endpoint, but the intervention is non-drug (electronic symptom monitoring). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Outer Retinal Tubulation and Vision in Geographic Atrophy: A Natural History Analysis From the Phase 3 OAKS and DERBY Trials. PMID 39918755 · Ophthalmic Surg Lasers Imaging Retina · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial. PMID 39914435 · Lancet Gastroenterol Hepatol · 2025-Apr The study is a randomized controlled trial with a drug intervention and a time-to-event primary endpoint, but it is not an oncology trial. The disease is chronic hepatitis B, and the primary endpoint is the prevention of liver-related serious adverse events (including hepatocellular carcinoma as a component), not the treatment of an existing malignancy. Therefore, it does not meet the required oncology criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Supporting older adults with cancer and their support person through geriatric assessment and remote exercise and education: The SOAR study protocol. PMID 39909737 · J Geriatr Oncol · 2025-Apr 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Safety of niraparib-based regimens in patients with ovarian cancer: A systematic review and meta-analysis. PMID 39908743 · Eur J Obstet Gynecol Reprod Biol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of My Tools for Care-in Care: A Pragmatic Randomized Controlled Trial. PMID 39904489 · J Am Med Dir Assoc · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial. PMID 39893343 · Ann Surg Oncol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CLpro detected in the SCORPIO-SR phase 3 trial. PMID 39892563 · Antiviral Res · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial. PMID 39884302 · Lancet Microbe · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of risankizumab for the treatment of patients with plaque type psoriasis. PMID 39882926 · Ital J Dermatol Venerol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Standard Versus Reduced Hydration to Improve Elimination of High-Dose Methotrexate in Pediatric Patients: A Controlled Crossover Trial. PMID 39868759 · Pediatr Blood Cancer · 2025-Apr Study is an oncology RCT with drug intervention (methotrexate) and original results, but it is a Phase II/pilot study (not Phase III/IIIb), and its primary endpoint is time to drug elimination (pharmacokinetic), not a survival or disease progression time-to-event efficacy endpoint (OS, PFS, DFS, etc.). No Kaplan-Meier curves or hazard ratios are reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Stereotactic body radiotherapy for non-spine bone metastases: A meta-analysis and international stereotactic radiosurgery society (ISRS) clinical practice guidelines. PMID 39862925 · Radiother Oncol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Fiber, lactose and fat-modified diet for the prevention of gastrointestinal chemo-radiotherapy-induced toxicity in patients with cervical cancer: Randomized clinical trial. PMID 39848009 · Nutrition · 2025-Apr The study is an oncology RCT with a time-to-event endpoint, but the intervention is dietary (fiber, lactose, fat modification) and not a drug. Phase is not explicitly stated as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prolonged vs standard thromboprophylaxis in patients with esophageal cancer undergoing surgery: a randomized controlled study. PMID 39842514 · J Thromb Haemost · 2025-Apr While the record is an original randomized controlled trial in oncology with a drug intervention (low-molecular-weight heparin), it does not meet the core requirement of having a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The primary endpoint was a biomarker (F1+2), and the secondary outcomes (venous thrombosis incidence, mortality) are not presented as time-to-event analyses with KM or HR. The trial phase is also not explicitly stated as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Grade ≥ 3 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis. PMID 39841181 · Eur J Clin Pharmacol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Aprocitentan for Blood Pressure Reduction in Black Patients. PMID 39840441 · Hypertension · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study. PMID 39828494 · Clin Breast Cancer · 2025-Apr The study is a randomized Phase II trial (ELAINE 1) with a drug intervention, but it reports on secondary patient-reported outcome (vaginal/vulvar symptoms) with descriptive statistics (mean changes in symptom scores), not a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR). |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Individualized transfusion decisions to minimize adverse cardiovascular outcomes in patients with acute myocardial infarction and anemia. PMID 39826701 · Am Heart J · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist. PMID 39821928 · Diabetes Obes Metab · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial. PMID 39820580 · Diabetologia · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty. PMID 39800203 · Am J Ophthalmol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Accounting for differential exclusions in the Nordic-European initiative on colorectal cancer trial discloses stronger-than-reported effects of screening colonoscopy. PMID 39800010 · J Clin Epidemiol · 2025-Apr The study is a randomized trial in human colorectal cancer (oncology). It is an original report of primary results. However, it evaluates a screening intervention (colonoscopy), not a drug-containing intervention. Furthermore, the primary endpoints are cancer incidence and risk reduction (relative risk, odds ratio), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier analysis with hazard ratio. Phase is not specified as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Refining Risk Stratification for B-cell Precursor Adult Acute Lymphoblastic Leukemia Treated With a Pediatric-inspired Regimen by Combining IKZF1 Deletion and Minimal Residual Disease. PMID 39798801 · Transplant Cell Ther · 2025-Apr The record describes a non-randomized cohort study evaluating risk stratification and outcomes with a drug-containing chemotherapy regimen, but it lacks evidence of randomization between treatment arms. Eligibility requires a randomized trial, so it is excluded despite other criteria being met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial. PMID 39797697 · BJU Int · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial. PMID 39791315 · Cancer Commun (Lond) · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. PMID 39789843 · Diabetes Obes Metab · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial. PMID 39781601 · Diabetes Obes Metab · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Recurrence-free survival after hepatectomy using propofol-based total intravenous anaesthesia and sevoflurane-based inhalational anaesthesia: a randomised controlled study. PMID 39776101 · Anaesthesia · 2025-Apr 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer. PMID 39746162 · J Clin Oncol · 2025-Apr The abstract describes a long-term follow-up and biomarker subgroup analysis of the C9741 trial. While it reports overall results (improved DFS and OS for dose-dense chemotherapy), the stated primary purpose and conclusion center on identifying the biomarker-defined subgroup (SET2,3) that benefits, making the report type 'subgroup'. Furthermore, the trial phase is not explicitly stated in the provided metadata (title, abstract, publication types, MeSH), preventing confirmation of the required Phase III/IIIb or Phase II/III criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial. PMID 39722400 · J Am Acad Dermatol · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial. PMID 39708985 · Gastroenterology · 2025-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS Trial. PMID 39707623 · Clin Pharmacol Ther · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |